FindTrial
Sign In

Preeclampsia Screening During Pregnancy Using a Rapid Test: A longitudinal study

A prospective longitudinal cohort study for Preeclampsia screening during pregnancy using a rapid test - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093428
Enrollment
200
Registered
2025-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O14- Pre-eclampsia

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Intignus Biotech Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant women

Exclusion criteria

Exclusion criteria: 1. Unconscious or severely ill status 2. Having major fetal abnormality identified at the time of enrollment 3. Known bleeding disorder such as von Willebrand?s disease 4. Participation in another drug trial within 28 days before screening 5. Pregnant women diagnosed with Preeclampsia

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of PEscreen in identifying women at risk of developing Preeclampsia compared to standard care of screening methodTimepoint: 4 time points—

Secondary

MeasureTime frame
Using patient history and other clinical findings (MAP, USG findings, maternal factors) and combinations for enhanced diagnostic accuracyTimepoint: 4 time points;Association of risk factors with PreeclampsiaTimepoint: 4 time points;Improved awareness among pregnant women surrounding topics of high risk pregnancies and preeclampsiaTimepoint: 4 time points—

Countries

India

Contacts

Public ContactDr Neha Lasure

Intignus Biotech Pvt Ltd

nehalasure@intignusbiotech.com9923141484

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026